Cellular stress response in human Milner cells (MIO-M1) after bevacizumab treatment

Autor(es)

Matsuda, Monique ; Krempel, Paloma Gava ; Marquezini, Monica Valeria ; Sholl-Franco, Alfred ; Lameu, Amanda ; Monteiro, Mario Luiz R. ; de Oliveira Miguel, Nadia Campos

• Tipo de documento: Artigo Científico
• Fonte: EXPERIMENTAL EYE RESEARCH; v. 160, p. 1-10, JUL 2017.
• Citações Web of Science: 2

Resumo

Bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, is widely used in the treatment of retinal vascular diseases. However, due to the essential role Muller cell derived VEGF plays in the maintenance of retinal neurons and glial cells, cell viability is likely to be affected by VEGF inhibition. We therefore evaluated the effect of bevacizumab-induced VEGF inhibition on Muller cells (MIO-M1) in vitro. MIO-M1 cells were cultured for 12 or 24 h in media containing bevacizumab at 0.25 or 0.5 mg/mL. Controls were cultured in medium only. Cell viability was determined with the trypan blue exclusion test and MTT assay. Caspase-3, beclin-1, glial fibrillary acidic protein (GFAP) and vimentin content were quantified by immunohistochemistry. Gene expression was evaluated by real-time quantitative PCR. Treatment with bevacizumab did not reduce MIO-M1 cell viability, but increased metabolic activity at 24 h (0.5 mg/mL) and induced apoptosis and autophagy, as shown by the increased caspase-3 levels at 12 h (0.25 and 0.5 mg/mL) and the increased beclin levels at 24 h (0.5 mg/mL). Caspase-3 mRNA was upregulated at 12 h and downregulated at 24 h in cells treated with bevacizumab at 0.25 mg/mL. Bevacizumab treatment was also associated with structural protein abnormalities, with decreased GFAP and vimentin content and upregulated GFAP and vimentin mRNA expression. Although bevacizumab did not significantly affect MIO-M1 cell viability, it led to metabolic and molecular changes (apoptosis, autophagy and structural abnormalities) suggestive of significant cellular toxicity. (C) 2017 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 11/12271-3 - Análise imunohistoquímica e de expressão gênica dos efeitos do bevacizumabe em explantes de retina de ratos lister e em uma linhagem celular de glia de Müller humana
• Beneficiário: Mário Luiz Ribeiro Monteiro
• Modalidade de apoio: Auxílio à Pesquisa - Regular